Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib + ADT + Abiraterone in Castration Sensitive Prostate Cancer
NCT04734730Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- May 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in prostate cancer (PCa), sponsored by City of Hope. Started May 2021; status: recruiting.
02
Drugs
talazoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04734730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734730.